Tenderwize
Retour à la recherche

Open House Original Rebate Contracts 2025-05 - Emtricitabine/Tenofovir Disoproxil/Rilpivirine (Active Combination)

Techniker Krankenkasse·Hamburg, Germany·Deadline Feb 27, 2027 · 185 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-05 - Emtricitabin/Tenofovirdisoproxil/Rilpivirin (Wirkstoffkombination)

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

30 / 100

Facteurs de risque

Patent expiry or loss of market exclusivity automatically terminates the contract for the affected drug. This may resul...

No guaranteed sales volume or revenue; the rebate contract does not ensure actual prescriptions or market share.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Feb 2027
  • Conclude rebate contracts for the drug combination Emtricitabine/Tenofovir Disoproxil/Rilpivirine
  • No individual negotiations; standard terms apply
Afficher le résumé complet

This is an Open House procedure (not a public procurement) by Techniker Krankenkasse and other German health insurers to conclude rebate contracts under §130c SGB V for the drug combination Emtricitabine/Tenofovir Disoproxil/Rilpivirine. The procedure is open continuously until the contract end date (28 February 2027) and all eligible pharmaceutical entrepreneurs with a valid marketing authorization for the drug combination can join on non-negotiable standard terms. No estimated value is published and no exclusivity is granted.

Risques

Patent expiry or loss of market exclusivity automatically terminates the contract for the affected drug. This may resul...

No guaranteed sales volume or revenue; the rebate contract does not ensure actual prescriptions or market share.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur under §4(18) AMG for the offered drug
  • Must have a valid marketing authorization or be otherwise entitled to market the drug combination
  • Must have registered seat within Germany, EU, or EEA

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open House Original Rebate Contracts 2025-05 - Emtricitabine/Tenofovir Disoproxil/Rilpivirine (Active Combination)

The objective is to conclude rebate contracts with all eligible pharmaceutical entrepreneurs for the drug combination Emtricitabine/Tenofovir Disoproxil/Rilpivirine under uniform, non-negotiable conditions. The contract runs from 1 March 2025 to 28 February 2027 (max. 24 months), but ends automatically upon patent expiry or loss of market exclusivity.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Feb 2025 - Feb 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Feb 27, 2027

Détails de la procédure

Date de publication
20 Jan 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
40386-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3